|Vilacto Bio Canada Patent LACTOACTIVE® Granted|
|By: Nasdaq / GlobenewsWire - 15 Mar 2019||Back to overview list
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Denmark-based Vilacto Bio Inc. (OTC QB:VIBI) is happy to announce that the Canadian Intellectual Property Office (CIPO) has informed the Company that its patent application for LACTOACTIVE® will be issued in near future.
The Company has already filed and received patents covering LACTOACTIVE® in the US, Europe and Hong Kong. The Canadian patent, when issued, is expected to give the company greater scope to continue developing the LACTOACTIVE® compound and bolster its international IP ownership position.
The patent applications in Canada also cover the Company’s new compound, LACTOACTIVE iTHER®, a LACTOACTIVE® variant that offers potent immune-system enhancement with a potential for treating a wide range of diseases. LACTOACTIVE iTHER® is expected to generate new revenue streams in addition to the company’s LACTOACTIVE®-based therapeutic skincare range.
“Vilacto Bio now is in a stronger position than ever to leverage the potential of LACTOACTIVE,” said Vilacto Bio CEO Gert Anderson.
The main active component of LACTOACTIVE® and LACTOACTIVE iTHER® is colostrum, a natural substance that Vilacto Bio has refined and processed into a potent nanoparticle concentrate. In NPDDS form, the compound can be applied in deeper layers of the skin and, when injected, can penetrate cell walls to act directly on cytoplasm. The product is currently in the development stage and has not been approved for use by the FDA or any foreign agency.
About Vilacto Bio Inc.:
Forward-Looking Statements & Disclaimers:
Vilacto Bio Inc.
Copyright 2019 Nasdaq / GlobenewsWire
|Back to overview list|